A validation of the 7.5% CO2 model of GAD using paroxetine and lorazepam in healthy volunteers

Journal of Psychopharmacology
Jayne BaileyDavid J Nutt

Abstract

The inhalation of 7.5% carbon dioxide (CO2) in healthy subjects produces an increase in blood pressure and heart rate, and increased feelings of anxiety, fear and tension (Bailey et al. 2005). As this state is similar to that of general anxiety rather than panic, we further validated this by examining the effects of anxiolytic medication. Two separate studies in healthy volunteers are described; study one is a double-blind, placebo-controlled study of a single dose of 2 mg lorazepam and study two describes the effects of 21 days of treatment with paroxetine. Gas challenges were air and 7.5% CO2 inhaled for 20 minutes, delivered on day 0 (before treatment) and day 21 (after treatment) in the paroxetine study. Subjective effects were measured using visual analogue scales and questionnaires. When compared with placebo, lorazepam 2 mg significantly reduced peak CO2-induced subjective fear, feelings of wanting to leave, tension and worry. In the paroxetine study, when compared with day 0, day 21 showed a significantly attenuated peak CO2-induced nervousness and a trend for reduced ratings of anxiety, fear, feel like leaving, tense and worried. In these studies we have shown that this CO2 model of anxiety is sensitive to lorazepam an...Continue Reading

References

Jun 17, 1992·European Journal of Pharmacology·E SannaG Biggio
Dec 1, 1991·Acta Psychiatrica Scandinavica·H PolsE Griez
Jul 1, 1984·The American Journal of Psychiatry·J M GormanD F Klein
Mar 1, 1982·Journal of Behavior Therapy and Experimental Psychiatry·D M Clark, D R Hemsley
Jun 1, 1995·Clinical Autonomic Research : Official Journal of the Clinical Autonomic Research Society·N J CouplandD Nutt
Jul 1, 1993·Progress in Neuro-psychopharmacology & Biological Psychiatry·A ConcasG Biggio
Aug 1, 1994·The American Journal of Psychiatry·W C SandersonG M Asnis
Nov 1, 1996·The Journal of Clinical Psychiatry·H J PolsE J Griez
Dec 5, 1997·Biological Psychiatry·J M GormanD F Klein
Jun 20, 1998·Biological Psychiatry·V BocolaN Martucci
Apr 13, 2002·Journal of Psychopharmacology·Caroline BellDavid J Nutt
May 15, 2002·Journal of Clinical Psychopharmacology·Giampaolo PernaLaura Bellodi
Jun 27, 2002·Psychoneuroendocrinology·Spilios V ArgyropoulosDavid J Nutt
Jul 20, 2002·Arquivos de neuro-psiquiatria·Alexandre M ValençaMárcio Versiani
Nov 27, 2002·Psychiatry Research·Alexandre M ValençaMarcio Versiani
Jan 25, 2003·Journal of Clinical Psychopharmacology·Angelo BertaniGiampaolo Perna
Dec 8, 2004·Journal of Psychopharmacology·Koen Schruers, Eric Griez
Mar 23, 2005·Depression and Anxiety·Jayne E BaileyDavid J Nutt
May 13, 2005·Journal of Psychopharmacology·Marlies A van DuinenEric J L Griez
Sep 17, 2005·Journal of Psychopharmacology·Stefano Zanone PomaEmilio Merlo-Pich

❮ Previous
Next ❯

Citations

Mar 29, 2012·Psychopharmacology·Matthew GarnerMarcus R Munafò
Jan 29, 2014·Brain Research·Kai MacDonald, David Feifel
Feb 11, 2012·Clinical Psychology Review·Kristin VickersAndrea Woznica
Apr 15, 2011·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Matthew GarnerMarcus R Munafò
Jul 16, 2016·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Borwin BandelowPeter Riederer
Mar 15, 2015·Journal of Psychiatric Research·Ben AinsworthMatthew Garner
Aug 27, 2016·Animals : an Open Access Journal From MDPI·Penny HawkinsHuw D R Golledge
Jul 7, 2016·Journal of Psychopharmacology·Katherine S ButtonAngela S Attwood
Nov 13, 2015·Journal of Psychopharmacology·Meg E FluhartyMarcus R Munafò
Apr 26, 2014·Journal of Psychopharmacology·Angela S AttwoodMarcus R Munafò
Oct 11, 2013·Journal of Psychopharmacology·Stefano Zanone PomaStefano Milleri
Mar 18, 2010·Journal of Psychopharmacology·Kate SeddonDavid J Nutt
Jun 22, 2019·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Christian GrillonMonique Ernst
Jun 20, 2012·Human Psychopharmacology·Danielle Chaves Gomes de OliveiraAntonio W Zuardi
Dec 4, 2012·The International Journal of Neuropsychopharmacology·Heiko GrafMartin Walter
Nov 7, 2019·Animals : an Open Access Journal From MDPI·Aline R SteinerThomas C Gent
Mar 15, 2020·The International Journal of Neuropsychopharmacology·Nathan T M HunekeMatthew Garner
Jun 3, 2017·Royal Society Open Science·Angela S AttwoodMarcus R Munafò
Dec 8, 2017·Translational Psychiatry·Nicholas L BalderstonChristian Grillon
Dec 14, 2019·Scientific Reports·Lucía AméndolaDaniel M Weary
Aug 23, 2020·Brain Sciences·Matteo VismaraBernardo Dell'Osso
Sep 29, 2019·Journal of Psychiatric Research·Julia TomasiArun K Tiwari
Oct 27, 2020·Journal of Psychopharmacology·Nicole K LeiboldKoen Rj Schruers
Mar 23, 2021·Frontiers in Human Neuroscience·Benjamin C GibsonVincent P Clark
Nov 8, 2020·Progress in Neuro-psychopharmacology & Biological Psychiatry·Priska KaufmannJasper Dingemanse
Dec 1, 2020·Journal of Psychiatric Research·Umit Tural, Dan V Iosifescu

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.